INTRODUCTION 77
Extended-spectrum β-lactamase (ESBL) or Amp-C β-lactamase (Amp-C)-producing 78
Enterobacteriaceae have been increasingly implicated in health care-and community-79 associated bacteremia (1). Effective treatment of ESBL or Amp-C bacteremia has become 80 a major challenge due to frequent resistance to various antibiotics and the existence of 81 mechanisms of co-resistance in this setting (2). At present, carbapenems are the treatment 82 of choice for ESBL bacteremia (3). However, increasing carbapenem resistance among 83
Enterobacteriaceae, as well as in other bacteria, calls for a more judicious approach to 84 carbapenem use (4). 85
86
Previous studies of empiric treatment of ESBL Enterobacteriaceae bacteremia with beta-87 lactam/beta-lactam inhibitor combinations (BL/BLIs) are contradictory (3, (5) (6) (7) . These 88 discrepant results may be due to differences in the source of infection, the genetic 89 background of the microorganism, or local epidemiology (8). Nevertheless, evidence is 90 emerging that empiric or definitive treatment with BL/BLIs is probably as effective as 91 carbapenem therapy in the setting of ESBL (E. coli or K. pneumoniae) bacteremia (9-11). 92
Data regarding the usefulness of carbapenem-sparing antibiotics other than BL/BLIs for 93 definitive treatment have also been reported, though also within an IV regimen (12) (13) (14) . 94
The effectiveness of non-intravenous (oral or intramuscular) antibiotic treatment for the 95 management of ESBL or Amp-C bacteremia has not been widely assessed to date (3, 15) . 96
At our cooperative non-profit private hospital, patients with ESBL or Amp-C 97
The aim of this study was to compare the 30-day mortality and clinical failure in two 103 groups: patients receiving carbapenems vs an alternative therapy, based on a non-IV 104 carbapenem-sparing antibiotic regimen, for the definitive treatment of ESBL or Amp-C-105 positive Enterobacteriaceae bacteremia. 106
METHODS 108

Study design, setting and participants 109
This 12-year retrospective study (January 2004 -December 2015 was conducted at a 110 tertiary general hospital, with 250 beds in Barcelona, Spain. Patients over age 15 with 111 community-acquired or healthcare-associated bacteremia due to ESBL or Amp-C-112 producing Enterobacteriaceae were included. Patients who died in the first 72h or those 113 without one-month follow-up were excluded. If patients experienced more than one 114 bacteremic episode, only the first episode was included. We recorded the prescribed 115 antibiotic in each case, as selected by the patient's attending physician. All episodes were 116 identified from the electronic microbiological database. The patients' clinical information 117 was collected from electronic clinical charts and electronic pharmacological database. The 118 follow up was performed by either the electronic clinical charts or by telephone if the 119 patient had been discharged. This study was approved by the institutional review board for 120 clinical trials. 121 122
End-points 123
The primary outcome measure was the 30-day mortality rate, and the secondary outcomes 124 were clinical failure within 30 days of onset of bacteremia and length of hospital stay. 125 were considered immunocompromised: those receiving corticosteroids at a dose of ≥20 134 mg prednisone or equivalent for ≥2 weeks, those with neutropenia (absolute neutrophil 135 count below 500/mm3) or those receiving anticancer chemotherapy in the previous six 136 months. Chronic kidney disease (CKD) was defined and staged according to the Kidney 137 Disease Improving Global Outcomes definition and classification (17). Charlson 138 comorbidity score was defined as previously described by Charlson et al (18) . The severity 139 of bacteremia on the day of onset was graded with the Pitt bacteremia score (19). Source 140 control was defined as any kind of intervention apart from antibiotic treatment applied to 141 solve the infection, such as surgical treatment, abscess drainage or catheter withdrawal. 142 Sepsis or septic shock was defined according to current definitions (20) . 143
Antimicrobial therapy was regarded as empirical if administered before the susceptibility 145 test results were available. Modification of treatment was defined as a change to an active 146 antibiotic after the culture result became available, in accordance with the pathogen's in 147 vitro susceptibility pattern. Definitive therapy was defined as an active antibiotic 148 administered for > 50% of the total duration of antimicrobial therapy after the antibiogram 149 result. Treatment was defined as appropriate when an active antimicrobial agent, 150 determined by in vitro susceptibility testing, was administered at the usual recommended 151 dose. Clinical failure was defined as persistence of bacteremia (i.e. positive blood cultures 152 for the same Enterobacteriaceae after 72 hours of active antibiotic treatment by in vitro 153 susceptibility), persistence of fever or sepsis, death, or relapse during a 30-day follow-up, 154 defined as positive blood cultures for the same microorganism (after a previous negative 155 result). Length of stay was defined as the time from the first positive blood culture to 156 discharge.
Microbiological identification and antibiotic susceptibility tests were carried out using the 160 During the study period, the microbiology department at our hospital did not have access 175
to PCR for the study of Amp C beta-lactamase-producing Escherichia coli. As we were 176 unable to establish whether E.coli-AmpC enzymes were encoded by chromosomal or 177 plasmid genes, we excluded all AmpC-E. coli to prevent potential confounding. 178 variables, as appropriate. Independent predictors for 30-day mortality were identified by 185 logistic regression analysis. 186
187
Given the lack of randomization of the initial therapies, a propensity score for receiving 188 carbapenems was estimated using a backward stepwise logistic regression model that 189 The in vitro susceptibility rate for various antibiotics for ESBL/Amp-C-producer strains was 211 as follows: carbapenem 100%, aminoglycosides 76%, piperacillin/tazobactam 59%, TMP-212 SMX 38%, amoxicillin/clavulanate 27% and quinolones 14%. 213
214
The most frequent infection sources were urinary (63%), biliary (15%) and unknown 215 source (8%), followed by catheter-related (6%), intra-abdominal (5%), surgical wound/soft 216 tissues (2%) and prosthetic joint infection (1%). The clinical and demographic 217 characteristics of each group are shown in Table 1 . There were no differences between 218 groups (carbapenems vs alternative therapy) in terms of age, comorbidity, infection 219 source, severity of underlying disease, time of empiric or definitive treatment. Compared to 220 the carbapenem group, the patients treated with the alternative regimen had lower median 221 Pitt score. 222
223
Source control was performed in five patients out of 42 (12%), in the alternative group: 224 three underwent catheter removal due to a catheter-related bacteremia and two underwent 225 endoscopic retrograde cholangiopancreatography due to a bacteremia of biliary source. 226
Source control was performed in ten patients out of 59 (17%), in the carbapenem group:three underwent endoscopic retrograde cholangiopancreatography, five required double J 228 catheter or percutaneous nephrostomy, one required debridement and implant retention, 229 and one needed an abdominal surgery. 230
231
During the 30-days of follow up, among the 59 carbapenem treated patients, 6 (10%) died 232 and 9 (15%) were considered as clinical failure (including the 6 patients who died), of 233 which 3 were due to bacteremia relapse. In the non-carbapenem group, two patients (5%) 234 died, which were also considered as clinical failure, and one of them had also previously 235 developed bacteremia relapse (Table1). The two patients who died in the alternative group 236 had a disseminated cancer (bladder and colon cancer). Among the 6 patients who died in 237 the carbapenem group one had a pancreas tumor and the rest of them were patients with 238 multiple comorbidities. (table 1) . 242
243
In the alternative treatment group, two patients receiving TMP-SMX died due to an ESBL 244 E. coli bacteremia (2/25 -8%), both of which had advanced neoplastic disease (as 245 previously described). This percentage is not higher than the 30 day mortality observed in 246 the carbapenem group (table 1) . 247 248
Alternative group 249
TMP-SMX was the most frequent therapeutic agent selected in these patients. The clinical 250 characteristics and source of bacteremia of patients who received alternative therapy as 251 definitive treatment are shown in table 2, and the complete therapy regimen and length of 252 therapy in the alternative group in table 3. When patients were switched to non-IVantibiotics, they had received a median of 2.5 days (IQR 0-6 days) of intravenous 254 appropriate therapy. 255
Multivariate and propensity score analysis 257
In the univariate analysis, nosocomial acquisition (OR 4.08; 95% CI 1.10-15.11; p=.035), 258 chronic kidney disease (OR 6.22 positive (5, 9, 12, 13, 23) and negative outcomes (24, 25) . In a metanalysis (3), the use of 277 empirical quinolones (oral or intravenous) for ESBL Enterobacteriaceae bacteremia was 278 associated with a higher mortality than carbapenems, but mortality was similar when 279 quinolones were used as definitive therapy. However, even in the carbapenem-sparing 280 setting, some studies have shown prior exposure to fluoroquinolones or β-lactam to be 281 independent risk factors for ESBL or carbapenem-resistant enterobacteriae infections (26, 282 27). Therefore, these antibiotics would probably not be the best options for the treatment 283 of these infections. carbapenems among a case series of pyelonephritis, however the outcome of patientstreated with TMP-SMX was not specified (29). TMP-SMX was the most frequent option 292 chosen as non-IV, carbapenem-sparing, definitive treatment in our study (mainly for 293 urinary and biliary sources); no complications were found related to this use. Our 294 experience with TMP-SMX, after confirming antibiotic susceptibility (38% of the strains of 295 ESBL infections in our setting), is promising. This option may prevent the emergence of 296 resistance, it allows for the administration of an oral regimen, and it could shorten the 297 hospital stay. which is crucial in order to contain the spread of carbapenem resistance (32), to reduce its 309 impact on global hospital ecology (33), and to shorten hospital stays. As demonstrated, 310 hospital stays in the alternative treatment group were significantly shorter in our study 311 population without a negative impact in terms of relapse or early re-admission. The 312 benefits associated with non-prolonged hospitalization in terms of cost-effectiveness and 313 comorbidity have been already demonstrated (34). 314 carbapenems without subsequent treatment with a non-carbapenem. All cases were 318 included in this retrospective study. Further, the sample size may be too small to achieve 319 adequate statistical power and selection by indication may bias the results. However we 320 tried to balance this limitation by adjusting our results using a propensity score analysis, 321 and did not observe changes in estimation effects. This study may not account for all the 322 variables that may have influenced the decision to use carbapenems and thus might 323 influence the OR; similarly, the goodness of model fit for calculating propensity score 324 weights might be underpowered (AUC=.77). We also could not characterize the ESBL 325 genes or investigate the MIC distribution for all study isolates. Finally, the study included 326 mostly bloodstream infections due to E. coli which means that these results cannot be 327 
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